Drug Discovery Featured Articles & Applications

1. Restoring Immune Homeostasis As A Development Approach To Treat And Modify Inflammatory Disease 10/8/2024

   Drawing from experiences with ongoing work at AnaptysBio, Inc., senior VP of research Martin Dahl, Ph.D., shares three considerations when developing immune cell modulators to treat and modify inflammatory disease.

2. Keys To Successful CMC Source Document Preparation For Cell & Gene Therapies 10/1/2024

   Chemistry, manufacturing, and controls (CMC) source documents are the foundation for module 3 of a cell/gene therapy FDA regulatory submission.

3. Tracking The Latest Developments In CAR T Safety And Efficacy 9/27/2024

   Here are some updates on the industry's quest to enhance CAR T cells' ability to target and destroy cancer while reducing adverse effects.

4. Araris Doubles Down With Dual-payload ADC 9/24/2024

   Antibody-drug conjugates usually deliver one payload type, which can overlook cancer’s complexity. A single ADC delivering two separate payloads could be the answer.

5. AI Is A Tool — Not A Replacement — For Human Innovation In Drug Discovery 9/4/2024

   This attorney provides practical advice. Can artificial intelligence (AI) make drug discovery easier? Yes! Will we lose the human component essential to the innovation culture? No.

6. Does Targeting Macrophages Hold The Key For Treating Cancer? 8/30/2024

   What is the role of macrophages, macrophage checkpoint inhibitors, and targeting immune receptor CD24 in treating cancer? What’s needed for clinical success in this space? 

7. Great siRNA Science Or Savvy Business Acumen? You Need Both 8/28/2024

   Silence Therapeutics has two wholly owned siRNA therapies now in clinical trials and one partnered program with AstraZeneca. Silence's CEO discusses the need for good science, making smart business decisions, and cultivating partnerships.

8. The Search For A Chemotherapy-Free Treatment For Patients With Blood Cancer 8/19/2024

   Blood cancer treatment options have long been limited and often come with serious short- and long-term side effects. AbbVie then is embarking on a new, chemotherapy-free way to treat this most common leukemia among adults.

9. Bridge RNAs: Principles, Applications, And Challenges 8/1/2024

   Bridge RNAs are structured noncoding RNAs that facilitate programmable recombination between target and donor DNA, enabling precise genomic rearrangements. A significant advantage is their modularity.

10. Is Your Lab Ready For A LIMS Implementation? 7/25/2024

    Deploying a laboratory information management system (LIMS) can boost your quality control lab's productivity, but how are you going about it? This article shares key steps and considerations for setting up your physical lab, controlling inventory, and more.